Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05670054
Other study ID # MD.22.07.674
Secondary ID
Status Recruiting
Phase Phase 3
First received
Last updated
Start date March 1, 2022
Est. completion date December 15, 2023

Study information

Verified date January 2023
Source Mansoura University
Contact manar hamed, MD
Phone +201063678209
Email manarhamed@mans.edu.eg
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Breast cancer is the commonest malignancy among females and one of the leading causes of death worldwide. Many drugs have been developed over the years to try to extend survival among these patients including cyclin dependant kinase inhibitors. Cyclin dependant kinase inhibitors (CDK inhibitors) mainly Palbociclib (PAL), ribociclib (RIB) and abemaciclib (ABM) are approved for treatment of hormone receptor positive, HER2 negative advanced breast cancer in the 1st line and subsequent lines in combination with aromatase inhibitors or fulvestrant. Studies showed that they extend progression free survival and recently they showed overall survival benefit. In this study investigators compare Palbociclib+ fulvestrant VS Ribociclib + fulvestrant as a second line treatment in metastatic ER+ve her2 -ve BC in oncology center mansoura university egyptian patients.


Description:

Breast cancer is the commonest malignancy among females and one of the leading causes of death worldwide. Many drugs have been developed over the years to try to extend survival among these patients including cyclin dependant kinase inhibitors. Cyclin dependant kinase inhibitors (CDK inhibitors) mainly Palbociclib (PAL), ribociclib (RIB) and abemaciclib (ABM) are approved for treatment of hormone receptor positive, HER2 negative advanced breast cancer in the 1st line and subsequent lines in combination with aromatase inhibitors or fulvestrant. Studies showed that they extend progression free survival and recently they showed overall survival benefit. In this study investigators compare Palbociclib+ fulvestrant VS Ribociclib + fulvestrant as a second line treatment in metastatic ER+ve her2 -ve BC in oncology center mansoura university egyptian patients. The efficacy and comparative toxicity of CDK inhibitors were indirectly compared in a number of trials. Despite differences in inclusion criteria and follow-up length, second-line trials showed similar characteristics. Unfortunately, despite the similar efficacy and overall response rate (ORR) and a slightly different but near-identical spectrum of adverse events, both agents have not been directly compared with each other. This study aims to fill that gap, and evaluate the toxicity, tolerability and response rate of ribociclib plus fulvestrant versus palbociclib plus fulvestrant, to inform the decision makers.


Recruitment information / eligibility

Status Recruiting
Enrollment 116
Est. completion date December 15, 2023
Est. primary completion date October 15, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - - Pathologically proven diagnosis of adenocarcinoma of the breast with evidence of metastatic disease either progression on adjuvant hormonal or progression on 1st line hormonal for metastatic disease. - Documentation of ER-positive and/or PR-positive and HER2 negative. - Prior use of endocrine therapy. - age >18 years old. - ECOG: 0-2 - Postmenopausal is defined as: age>60 years old or < 60 years old with cessation off menstruation for at least 12 months and FSH or E2 in postmenopausal range or patients who underwent bilateral oophorectomy. - Premenopausal is defined if not meeting the criteria of postmenopausal. They are obligated to receive LHRH agonist with their treatment. Exclusion Criteria: - - Age < 18 years old - Patients with advanced/metastatic, symptomatic, visceral spread(visceral crisis) , that are at risk of life-threatening complications in the short term (including patients with massive uncontrolled effusions [pleural, pericardial, peritoneal], pulmonary lymphangitis, and over 50% liver involvement). - 2nd malignancy other than breast cancer - ECOG more than 3

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
comparing both arms as regard the objective response rate, toxicity profile, quality of life, progression free survival
comparing both arms as regard the objective response rate, toxicity profile, quality of life, progression free survival

Locations

Country Name City State
Egypt Oncology center mansoura university Mansoura Dakahlia

Sponsors (1)

Lead Sponsor Collaborator
Mansoura University

Country where clinical trial is conducted

Egypt, 

Outcome

Type Measure Description Time frame Safety issue
Primary The rate of objective response and clinical benefit compare objective response rate and clinical benefit rate between the 2 arms the last patient recruited in the study will be followed up for at least 6 months
Primary Incidence and grade of toxicity compare the incidence and grade of toxicity between the 2 arms the last patient recruited in the study will be followed up for at least 6 months
Primary Compare Quality of life score of the patients using EORTC core quality of life questionaire version C-30 compare the level of deterioration of the quality of life score between the 2 arms each patient will answer the QOL score at D0, 3rd and 6 months of treatment as long as he is hasn't progressed on treatment during the 1st 6 months
See also
  Status Clinical Trial Phase
Not yet recruiting NCT04469127 - A Phase I/II Multicenter, Open-Label Study of Lu-177-DOTAGA-IAC, for the Treatment of Angiogenic Breast Cancer Patients. Phase 1/Phase 2
Withdrawn NCT03032614 - Combination of Carboplatin, Eribulin and Veliparib in Stage IV Cancer Patients Phase 2
Terminated NCT04123704 - Sitravatinib in Metastatic Breast Cancer Phase 2
Recruiting NCT05377047 - Stereotactic Ablative Radiotherapy for OligoMetastatic Breast Cancer N/A
Completed NCT03304210 - PIPAC Nab-pac for Stomach, Pancreas, Breast and Ovarian Cancer Phase 1
Completed NCT05054374 - A Study of Mirdametinib on Its Own or in Combination With Fulvestrant in People With Solid Tumor Cancer Phase 1/Phase 2
Recruiting NCT05559528 - BRaziLian outcomE for metAStatic breasT Cancer
Active, not recruiting NCT05090358 - Preventing High Blood Sugar in People Being Treated for Metastatic Breast Cancer Phase 2
Recruiting NCT05033925 - Ficus Septica Leaves Fraction as a Complementary Therapy for Stadium IV Breast Cancer Patients Phase 1/Phase 2
Recruiting NCT03401359 - The Resistance and Immune Response to Palbociclib in Breast Cancer N/A
Active, not recruiting NCT03870919 - Locoregional Treatment and Palbociclib in de Novo, Treatment Naive, Stage IV ER+, HER2- Breast Cancer Patients N/A
Not yet recruiting NCT05860907 - Clinical Study of Huaier Granules in Patients With Advanced Breast Cancer Without Visceral Metastasis Phase 4
Completed NCT00393341 - Quantitation of Endothelial Progenitor Cells as Markers of Tumor Angiogenesis in Breast Cancer N/A
Recruiting NCT05625087 - Detection of Tumor DNA in the Blood of Patients Receiving Standard Therapy for Hormone Receptor-positive (HR+) Non-HER2 Expressing (HER2-) Metastatic Breast Cancer as a Tool to Select Those Who May Benefit From the Next Course of Fulvestrant in Combination With Alpelisib or Ribociclib Phase 2
Completed NCT04566458 - RWD Study in HER2+ mBC Patients in Third-Line Therapy
Recruiting NCT06075810 - A Study of Oral MBQ-167 in Participants With Advanced Breast Cancer Phase 1
Recruiting NCT04697043 - The Benefit of Surgery in Stage IV of Breast Cancer N/A
Recruiting NCT05837533 - Multicenter Study to Evaluate a Systematized Communication Model for Breast Cancer Patients N/A
Active, not recruiting NCT03324425 - Simvastatin Plus Dual Anti-HER2 Therapy for Metastatic Breast Cancer Phase 2
Terminated NCT03202446 - Randomized Clinical Trial Evaluating the Use of the Laser-Assisted Immunotherapy (LIT/inCVAX) in Advanced Breast Cancer Phase 3